We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    2020-001665-37
Previous Study | Return to List | Next Study

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04490018
Recruitment Status : Completed
First Posted : July 28, 2020
Last Update Posted : May 25, 2022
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )

Brief Summary:

Primary Objective:

To demonstrate the non-inferiority of the seroprotection rate (serum bactericidal assay using human complement [hSBA] titer ≥ 1:8) to meningococcal serogroups A, C, W, and Y following the administration of a single dose of MenACYW conjugate vaccine (Group 1) compared to a single dose of Nimenrix® (Group 2)

Secondary Objective:

To describe:

  • the antibody response of meningococcal serogroups A, C, W, and Y measured by hSBA, before and 1 month following meningococcal vaccination administered alone (Groups 1 and 2) or concomitantly with 9-valent human papilloma virus (9vHPV) and tetanus, diphtheria, and acellular pertussis - inactivated polio vaccine [adsorbed, reduced antigen(s) content] (Tdap-IPV) vaccines (Group 3)
  • the antibody response of meningococcal serogroup C measured by hSBA and serum bactericidal assay using baby rabbit complement (rSBA), before vaccination and at Day 31 after vaccination with MenACYW conjugate vaccine or Nimenrix® (Groups 1 and 2) according to MenC primed status
  • the antibody response against antigens of 9vHPV and Tdap-IPV vaccines, before and 1 month following vaccination
  • the safety profile in each group after each and any vaccination

Condition or disease Intervention/treatment Phase
Meningococcal Infection (Healthy Volunteers) Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine Biological: Meningococcal group A, C, W-135, and Y conjugate vaccine Biological: Human Papillomavirus 9-valent Vaccine 9vHPV Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine Tdap-IPV Phase 3

Detailed Description:

The duration of study participation for each participant will be approximately 30 to 60 days, including 2 or 3 visits (1 or 2 vaccination visit) and 1 or 2 telephone calls, depending on study Group.

* This is the first dose of 9vHPV, of the 2-dose or 3-dose series according to the local recommendations and age of the participant. These additional vaccinations for the completion of 9vHPV schedule will take place outside of the objectives and scope of this study and thus will not be described in this protocol.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 464 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a parallel group prevention study with 2 groups that are observer blind (only the person administering the vaccine is unblinded), and 1 group that is open-label
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:

The study will be performed in a partially observer-blind fashion:

In Groups 1 and 2

  • Investigators and study staff who conduct the safety assessment, participants, parents/legally acceptable representatives, the Sponsor, and laboratory personnel performing the serology testing will be kept blinded to the vaccine received
  • Only the study staff who prepare and administer the vaccine and are not involved with the safety evaluation will know which vaccine is administered In Group 3
  • Everyone involved in the study (ie, Investigator, study staff, the Sponsor, participants, parents/legally acceptable representatives) will know which vaccine is administered. This open-label design for Group 3 is due to the different vaccination schedule for this group than for Groups 1 and 2
Primary Purpose: Treatment
Official Title: Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly With 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents
Actual Study Start Date : March 16, 2021
Actual Primary Completion Date : May 11, 2022
Actual Study Completion Date : May 11, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1 (investigational group - sequential administration)
MenACYW conjugate vaccine on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
Pharmaceutical form:Liquid solution for injection Route of administration: Intramuscular
Other Name: MenQuadfi®

Biological: Human Papillomavirus 9-valent Vaccine 9vHPV
Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Other Name: Gardasil® 9

Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine Tdap-IPV
Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Other Name: Repevax®/Triaxis®/Adacel®Polio

Active Comparator: Group 2 (control group - sequential administration)
Nimenrix® on Day 01 and 9vHPV* + Tdap-IPV vaccines on Day 31: n=174
Biological: Meningococcal group A, C, W-135, and Y conjugate vaccine
Pharmaceutical form:Powder and solvent for solution for injection Route of administration: Intramuscular
Other Name: Nimenrix®

Biological: Human Papillomavirus 9-valent Vaccine 9vHPV
Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Other Name: Gardasil® 9

Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine Tdap-IPV
Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Other Name: Repevax®/Triaxis®/Adacel®Polio

Experimental: Group 3 (investigational group - concomitant administration)
MenACYW conjugate vaccine + 9vHPV* + Tdap-IPV vaccines on Day 01: n=116
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
Pharmaceutical form:Liquid solution for injection Route of administration: Intramuscular
Other Name: MenQuadfi®

Biological: Human Papillomavirus 9-valent Vaccine 9vHPV
Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Other Name: Gardasil® 9

Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine Tdap-IPV
Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Other Name: Repevax®/Triaxis®/Adacel®Polio




Primary Outcome Measures :
  1. Seroprotection against meningococcal serogroups A, C, W, and Y: Group 1 and Group 2 [ Time Frame: Day 31 ]
    Antibody titers measured by hSBA in Groups 1 and 2 Seroprotection defined as antibody titer equal or greater than (≥) 1:8


Secondary Outcome Measures :
  1. Antibody titers against meningococcal serogroups A, C, W, and Y [ Time Frame: Day 01 (pre-vaccination) and Day 31 (post-vaccination) ]
    Antibody titers measured by hSBA in each group

  2. Antibody titers against meningococcal serogroup C [ Time Frame: Day 01 (pre-vaccination) and Day 31 (post-vaccination) ]
    Antibody titers measured by serum bactericidal assay using rSBA in Group 1 and Group 2

  3. Antibodies titers against antigens contained in Tdap-IPV vaccine: Group 1 and Group 2 [ Time Frame: Day 31 (pre-vaccination) and Day 61 (post-vaccination) ]
    Anti-Polio 1, 2, and 3 antibody titers measured in Group 1 and Group 2

  4. Antibodies titers against antigens contained in Tdap-IPV vaccine: Group 3 [ Time Frame: Day 01 (pre-vaccination) and Day 31 (post-vaccination) ]
    Anti-Polio 1, 2, and 3 antibody titers measured in Group 3

  5. Antibodies concentrations against antigens contained in Tdap-IPV vaccine: Group 1 and Group 2 [ Time Frame: Day 31 (pre-vaccination) and Day 61 (post-vaccination) ]
    Anti-tetanus, anti-diphtheria and anti-pertussis antibody concentrations measured in Group 1 and Group 2

  6. Antibodies concentrations against antigens contained in Tdap-IPV vaccine: Group 3 [ Time Frame: Day 01 (pre-vaccination) and Day 31 (post-vaccination) ]
    Anti-tetanus, anti-diphtheria and anti-pertussis antibody concentrations measured in Group 3

  7. Antibodies titers against antigens contained in HPV vaccine: Group 1 and Group 2 [ Time Frame: Day 31 (pre-vaccination) and Day 61 (post-vaccination) ]
    Anti-HPV antibody titers measured in Group 1 and Group 2

  8. Antibodies titers against antigens contained in HPV vaccine: Group 3 [ Time Frame: Day 01 (pre-vaccination) and Day 31 (post-vaccination) ]
    Anti-HPV antibody titers measured in Group 3

  9. Number of participants reporting immediate adverse events (AEs) [ Time Frame: Within 30 minutes post-vaccination ]
    Unsolicited systemic AEs reported in the 30 minutes after each vaccination

  10. Number of participants reporting solicited injection site reactions and systemic reactions [ Time Frame: Within 7 days post-vaccination ]
    Solicited (prelisted in the participant's diary card and [electronic] Case Report Form [CRF]) injection site and systemic reactions starting any time from the day of vaccination through 7 days after each vaccination Injection site reactions: pain, erythema and swelling Systemic reactions: fever, headache, malaise, myalgia

  11. Number of participants reporting unsolicited non-serious AEs [ Time Frame: Within 30 days post-vaccination ]
    Unsolicited (recorded in a diary card) non-serious AEs reported up to 30 days after each vaccination

  12. Number of participants reporting serious adverse events (SAEs) [ Time Frame: Up to Day 61 post-vaccination ]
    Serious adverse events (SAEs) (including adverse events of special interest [AESIs]) reported throughout the study, i.e., from Day 01 (first vaccination) to the last study day (Day 61 for Groups 1 and 2 and Day 31 for Group 3)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged 10 to 17 years on the day of inclusion ('10 to 17 years' means from the day of the 10th birthday to the day before the 18th birthday)
  • Meningococcal C conjugate (MenC) naïve participants or participants having received monovalent MenC priming in infancy (< 2 years of age)
  • Assent form has been signed and dated by the participant as per local regulation, and Informed Consent Form has been signed and dated by the parent/legally acceptable representative and by the participant if she/he turns 18 years old during the study
  • Participants and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all study procedures
  • Covered by health insurance, if required by local regulations

Exclusion Criteria:

  • Participant is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after last vaccination. To be considered of non-childbearing potential, a female must be pre-menarche
  • Previous vaccination against meningococcal disease with either the study vaccine or another vaccine (ie, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, W, or Y; or meningococcal B serogroup-containing vaccine), except licensed monovalent MenC vaccination received before 2 years of age
  • Participation at the time of study enrollment (or in the 4 weeks preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Receipt of any vaccine in the 4 weeks preceding any study vaccination or planned receipt of any vaccine in the 4 weeks following any study vaccination except for influenza vaccination, which may be received at least 2 weeks before study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • History of vaccination with any tetanus, diphtheria, pertussis, or inactivated polio virus vaccine within the previous 3 years
  • Previous human papilloma virus (HPV) vaccination
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
  • Known history of diphtheria, tetanus, pertussis, poliomyelitis, and/or HPV infection or disease.
  • Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances
  • Personal history of Guillain-Barré syndrome
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination
  • Personal history of new or past encephalopathy, progressive or unstable neurological disorder, or unstable epilepsy
  • Verbal report of thrombocytopenia, contraindicating intramuscular vaccination
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Current alcohol abuse or drug addiction
  • Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to Investigator's judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0 C [≥ 100.4 F]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
  • Participant at high risk for meningococcal infection during the study (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04490018


Locations
Show Show 23 study locations
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi Pasteur, a Sanofi Company
ClinicalTrials.gov Identifier: NCT04490018    
Other Study ID Numbers: MEQ00071
2020-001665-37 ( EudraCT Number )
U1111-1249-2973 ( Registry Identifier: ICTRP )
First Posted: July 28, 2020    Key Record Dates
Last Update Posted: May 25, 2022
Last Verified: May 18, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Meningococcal Infections
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses
Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs